Abstract |
The antianginal efficacy of molsidomine (single oral dose of 2 mg), a new antianginal drug, was evaluated in 12 patients with coronary artery disease in a double-blind randomized placebo-controlled study by bicycle ergometry. Besides the standard ergometric parameters, the myocardial efficiency index (MEI) was determined from the ratio of the maximum workload (kgm/min) to double product (mm Hg X min) X 10(-2), normalized for body surface area. Compared to placebo, molsidomine decreased positive exercise tests by 50%, pain response by 66%, and the magnitude of ST depression by 43%. Furthermore, the onset of ergometric positive response was delayed, with an increase in maximum workload achieved (+21%), total work performed (+43%), and duration of exercise (+28%). MEI also increased from 0.98 +/- 0.43 to 1.18 +/- 0.44 (p less than 0.005), due to a significant increase in maximal workload without a parallel increase in double product. These findings suggest that molsidomine is an effective antianginal drug and improves myocardial efficiency in patients with angina due to coronary artery disease.
|
Authors | F R Mindlin de Aptecar, A Vazquez, M Aptecar |
Journal | Cardiology
(Cardiology)
Vol. 72
Issue 4
Pg. 185-92
( 1985)
ISSN: 0008-6312 [Print] Switzerland |
PMID | 3902224
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Oxadiazoles
- Sydnones
- Molsidomine
|
Topics |
- Aged
- Angina Pectoris
(complications, drug therapy, physiopathology)
- Clinical Trials as Topic
- Double-Blind Method
- Exercise Test
- Female
- Humans
- Hypertension
(complications)
- Male
- Middle Aged
- Molsidomine
- Myocardial Infarction
(complications)
- Myocardium
(metabolism)
- Oxadiazoles
(therapeutic use)
- Oxygen Consumption
(drug effects)
- Random Allocation
- Sydnones
(therapeutic use)
|